However, regarding the vital role of IL-6 in ACD, a recent study reported a significant increase in Hb and Hct levels after IL-6 receptor inhibitor tocilizumab (TCZ) therapy in anemic and non-anemic patients with rheumatoid arthritis, compared with other biologic and non-biologic disease-modifying antirheumatic drugs (DMARDs) [60]. This evidence concerns the gene IL6 and rheumatoid arthritis.